Unknown

Dataset Information

0

The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab.


ABSTRACT: This prospective study was to investigate the value of [11C]-acetate PET and [18F]-FDG PET in the evaluation of hepatocellular carcinoma (HCC) before and after treatment with transarterial chemoembolization (TACE) and vascular endothelial growth factor (VEGF) antibody (bevacizumab).Twenty-two patients (three women, 19 men; 62 ± 8 years) with HCC verified by histopathology were treated with TACE and bevacizumab (n = 11) or placebo (n = 11). [11C]-acetate PET and [18F]-FDG PET were performed before and after TACE with bevacizumab or placebo. Comparisons between groups were performed with t-tests and Chi-squared tests, where appropriate. Overall survival (OS) was defined as the time from start of bevacizumab or placebo until the date of death/last follow-up, respectively.The patient-related sensitivity of [11C]-acetate PET, [18F]-FDG PET, and combined [11C]-acetate and [18F]-FDG PET was 68%, 45%, and 73%, respectively. There was a significantly higher rate of conversion from [11C]-acetate positive lesions to negative lesions in patients treated with TACE and bevacizumab as compared with that in patients with TACE and placebo (p < 0.05). In patients with negative acetate PET, the mean OS in patients treated with TACE and bevacizumab was 259 ± 118 days and was markedly shorter as compared with that (668 ± 217 days) in patients treated with TACE and placebo (p < 0.05). In patients treated with TACE and placebo, there was significant difference in mean OS in patients with positive FDG PET as compared with that in patients with negative FDG PET (p < 0.05). The HCC lesions had different tracer avidities showing the heterogeneity of HCC.Our study suggests that combining [18F]-FDG with [11C]-acetate PET could be useful for the management of HCC patients and might also provide relevant prognostic and molecular heterogeneity information.

SUBMITTER: Li S 

PROVIDER: S-EPMC5537334 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

The value of [<sup>11</sup>C]-acetate PET and [<sup>18</sup>F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab.

Li Shuren S   Peck-Radosavljevic Markus M   Ubl Philipp P   Wadsak Wolfgang W   Mitterhauser Markus M   Rainer Eva E   Pinter Matthias M   Wang Hao H   Nanoff Christian C   Kaczirek Klaus K   Haug Alexander A   Hacker Marcus M  

European journal of nuclear medicine and molecular imaging 20170529 10


<h4>Purpose</h4>This prospective study was to investigate the value of [<sup>11</sup>C]-acetate PET and [<sup>18</sup>F]-FDG PET in the evaluation of hepatocellular carcinoma (HCC) before and after treatment with transarterial chemoembolization (TACE) and vascular endothelial growth factor (VEGF) antibody (bevacizumab).<h4>Methods</h4>Twenty-two patients (three women, 19 men; 62 ± 8 years) with HCC verified by histopathology were treated with TACE and bevacizumab (n = 11) or placebo (n = 11). [<  ...[more]

Similar Datasets

| S-EPMC5556938 | biostudies-literature
| S-EPMC6156070 | biostudies-literature
| S-EPMC10517195 | biostudies-literature
| S-EPMC6150287 | biostudies-literature
| S-EPMC3787881 | biostudies-literature
| S-EPMC7226577 | biostudies-literature
| S-EPMC6788704 | biostudies-literature
| S-EPMC7584088 | biostudies-literature
| S-EPMC7465161 | biostudies-literature
| S-EPMC6002865 | biostudies-literature